Immunic Psoriasis Analysis Adds Dose Of Uncertainty To Program

 
• By Alaric DeArment

Without disclosing full Phase Ib data, the company reported a higher-than-expected placebo response versus IMU-935. With its second setback this year Immunic has a long path to meaningful data.

Immunic announced an interim analysis of its Phase Ib study of IMU-935 in psoriasis • Source: Shutterstock

More from Strategy

More from Business